Sep 2025 (Q3 FY25) — Nov 4, 2025
Franco-Nevada Q3 FY25 — Third consecutive record quarter on high gold prices, new gold acquisitions and Cobre Panama stockpile sales
Read the full callFranco Nevada earnings: last reported Tue, 4 Nov 2025, for the quarter ended Sep 2025.
Price
1Y: $203.69 on 17 Oct 2025 → $241.58. High $280.82 (26 Feb 2026), low $183.97 (27 Oct 2025).
Overview
Call summaries
Franco-Nevada Q3 FY25 — Third consecutive record quarter on high gold prices, new gold acquisitions and Cobre Panama stockpile sales
Read the full callFranco-Nevada Q2 FY25 — Record Financials Driven by High Gold Prices and Portfolio Growth
Read the full callEvery analysed call
Financials
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities | 300 | 218 | 149 | 185 | 209 | 225 | 334 | 606 |
| Total assets | 4,932 | 5,281 | 5,593 | 6,210 | 6,627 | 5,994 | 6,330 | 8,241 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 475 | 618 | 804 | 955 | 1,000 | 991 | 830 | 1,494 |
| Cash from investing | -989 | -436 | -309 | -765 | -145 | -541 | -537 | -2,033 |
| Cash from financing | 78 | -120 | -92 | -180 | -189 | -230 | -240 | -267 |
| Net cash flow | -441 | 62 | 402 | 5 | 657 | 225 | 29 | -780 |
| Capital expenditure | — | — | — | — | — | — | -0 | -2 |
| Free cash flow | — | — | — | — | — | — | 829 | 1,491 |
No filings in the last 12 months.
No officer, director or 10% owner of FNV filed a Form 4 in this window. That is a statement about filings, not about ownership — see the note below.
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow FRANCO NEVADA Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading